EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework

Clementina Elvezia Cocuzza iD, Sharonjit Kaur Dhillon, Marianna Martinelli iD, Chiara Giubbi iD, Ruth Chinyere Njoku iD, Ramya Bhatia iD, Kate Cuschieri iD, Marc Arbyn iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Clementina Elvezia Cocuzza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network, Horizon 2020 SME Instrument Phase 2 Project: HPV OncoPredict.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical validation of human papillomavirus (HPV) assays according to international criteria is prerequisite for their implementation in cervical cancer screening. OncoPredict HPV Quantitative Typing (QT) assay (Hiantis Srl, Milan, Italy) is a novel full‐genotyping multiplex real‐time PCR quantitative assay targeting E6/E7 genes, allowing individual viral load determination of 12 high‐risk (HR) HPV types. Quality controls for sample adequacy, efficiency of nucleic acid extraction and PCR inhibition are included in the assay. Clinical performance of OncoPredict HPV QT test was assessed as part of the “Validation of HPV Genotyping Tests” (VALGENT‐2) framework, consisting of 1300 cervical liquid‐based cytology (LBC) samples of women aged between 20 and 60 years who had originally attended for routine cervical screening in Scotland. The clinical accuracy of the OncoPredict HPV QT (index test) for the detection of CIN2+ was assessed relative to the GP5+/6+ Enzyme ImmunoAssay (GP5+/6+ EIA) (comparator test), using noninferiority criteria. Intra‐ and interlaboratory reproducibility of the assay was assessed on a subpopulation, comprising 526 samples. The relative sensitivity and specificity for OncoPredict HPV QT vs GP5+/6+‐PCR‐EIA were 1.01 (95% CI: 0.99‐1.03) and 1.03 (95% CI: 1.0‐1.06) respectively. The P‐ values for noninferiority were ≤0.001. The intra‐ and inter‐laboratory reproducibility demonstrated a high concordance (>98.7%) with kappas for individual types ranging from 0.66 to 1.00. OncoPredict HPV QT fulfills the international validation criteria for the use of HPV tests in cervical cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsUterine Cervical DysplasiaPapillomavirus InfectionsFemaleHumansYoung AdultAdultMiddle AgedGenotypeEarly Detection of CancerGenotyping TechniquesReproducibility of ResultsPapillomaviridaeSensitivity and Specificity

Stichwörter der Autor:innen

OncoPredict HPV quantitative typing (QT)VALGENT frameworkcervical cancer preventionclinical performance studyfull-genotyping HPV viral load

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Unit of Cancer Epidemiology/Belgian Cancer Centre, Sciensano, Brussels, Belgium.
  • HPV Research Group, Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
  • Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.

ORCID-Profile: Clementina Elvezia Cocuzza, Marianna Martinelli, Chiara Giubbi, Ruth Chinyere Njoku, Ramya Bhatia, Kate Cuschieri, Marc Arbyn

Förderung

  • Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network
  • Horizon 2020 SME Instrument Phase 2 Project: HPV OncoPredict

Zitieren

APA

Cocuzza, C. E., Dhillon, S. K., Martinelli, M., Giubbi, C., Njoku, R. C., Bhatia, R., Cuschieri, K., & Arbyn, M. (2024). Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework. International Journal of Cancer. https://doi.org/10.1002/ijc.34754

Vancouver

Cocuzza CE, Dhillon SK, Martinelli M, Giubbi C, Njoku RC, Bhatia R, et al. Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework. International Journal of Cancer. 2024. doi:10.1002/ijc.34754

BibTeX
@article{Cocuzza2024,
  author = {Cocuzza, Clementina Elvezia and Dhillon, Sharonjit Kaur and Martinelli, Marianna and Giubbi, Chiara and Njoku, Ruth Chinyere and Bhatia, Ramya and Cuschieri, Kate and Arbyn, Marc},
  title = {Clinical performance of the novel full‐genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34754}
}
Kostenlos starten →